U.S. Luxury Stock News

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

We'd be surprised if Olaplex Holdings, Inc. ( NASDAQ:OLPX ) shareholders haven't noticed that the CEO & Director...

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...

You may think that with a price-to-sales (or "P/S") ratio of 0.9x SolarMax Technology, Inc. ( NASDAQ:SMXT ) is a stock...

Fox Factory Holding Corp. ( NASDAQ:FOXF ) shareholders are no doubt pleased to see that the share price has bounced 25...

We wouldn't blame MercadoLibre, Inc. ( NASDAQ:MELI ) shareholders if they were a little worried about the fact that...

With a price-to-earnings (or "P/E") ratio of 16.7x Granite Ridge Resources, Inc. ( NYSE:GRNT ) may be sending bullish...

Anyone interested in Simpson Manufacturing Co., Inc. ( NYSE:SSD ) should probably be aware that the Independent Chair...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...

Key Insights Given the large stake in the stock by institutions, First Internet Bancorp's stock price might be...

Aehr Test Systems, Inc. ( NASDAQ:AEHR ) shareholders might be concerned after seeing the share price drop 23% in the...

Earlier this month, Udemy announced a new AI-powered microlearning experience and a partnership with LG CNS that brings its AI learning platform to more than 500 Korean enterprises via LG CNS’s AX Platform. Together, these moves highlight how Udemy is using AI to reshape course delivery while tapping Korea’s innovation-focused corporate sector to deepen its enterprise footprint across Asia-Pacific. We’ll now look at how Udemy’s AI-driven microlearning rollout, especially its LG CNS...

Earlier in 2025, JLL’s Capital Markets group arranged US$306 million in senior non-recourse construction financing and US$78 million in preferred equity for the 678-unit Harborside 8 luxury waterfront multifamily project in Jersey City, with Kennedy-Wilson providing the floating-rate senior loan. This financing deepens Kennedy-Wilson’s partnership with the development team and underscores its focus on large-scale, higher-end rental housing projects in growth corridors. We’ll now examine how...

Merus (MRUS) has quietly turned into one of the stronger biotech performers this year, with the stock up more than 120% year to date as investors reprice its antibody pipeline potential. See our latest analysis for Merus. That kind of rerating has not come out of nowhere, with Merus enjoying a powerful 90 day share price return of 42.16% and a standout three year total shareholder return of 597.77%. This suggests momentum is still firmly building around its pipeline story. If Merus has caught...

iRobot (IRBT) just hit two major turning points at once: a voluntary Chapter 11 filing and a Nasdaq delisting notice, effectively signaling the endgame for its public equity story. See our latest analysis for iRobot. Those Chapter 11 and delisting headlines basically crystallise what the share price had been hinting at for a while. A 1 year total shareholder return of around minus 91 percent and multi year losses show that momentum has not just faded; it has largely evaporated, as equity...

B. Riley Financial (RILY) has swung back to positive quarterly earnings in Q2 2025, posting revenue of about $199 million and EPS of roughly $2.23, even as trailing 12 month figures still reflect sizable losses. The company has seen revenue move from about $38 million in Q2 2024 to nearly $199 million in Q2 2025, while quarterly EPS has shifted from roughly negative $14.86 to positive $2.23. This sets up a sharp contrast between the latest quarter and its loss making recent history and puts...

Yext (YEXT) has quietly outperformed many software peers this year, and that kind of steady climb usually means investors see something durable in the story, not just a passing sentiment shift. See our latest analysis for Yext. At a share price of $8.51, Yext’s steady year to date share price return of just over 30 percent and 1 year total shareholder return above 31 percent suggest momentum is still building as investors reassess its growth and profitability profile. If Yext’s climb has you...

Caleres, Inc. ( NYSE:CAL ) will pay a dividend of $0.07 on the 9th of January. Based on this payment, the dividend...

Key Insights Given the large stake in the stock by institutions, Digimarc's stock price might be vulnerable to their...

Recently, SNDL Inc. renewed its share repurchase program of up to C$100 million and saw sentiment strengthen after reports that the Trump administration may push to reclassify marijuana to Schedule III in the US, a move that could ease tax and financing constraints across the cannabis industry. Although SNDL remains primarily focused on Canada, shifting expectations around US federal cannabis policy are increasingly influencing how investors view its long-term optionality and capital...

As the U.S. stock market experiences a retreat following delayed jobs data and higher-than-expected unemployment rates, investors are closely monitoring economic indicators and Federal Reserve decisions for future guidance. In such an environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to invest wisely amid market fluctuations.

In a period marked by the retreat of major stock indexes following unexpected unemployment data, investors are closely examining growth companies with high insider ownership as potential opportunities. In today's market, where economic indicators can sway investor sentiment, stocks with strong earnings growth and significant insider stakes may offer unique insights into company confidence and long-term potential.

In the current landscape, major U.S. stock indices like the Dow Jones and S&P 500 have recently retreated, influenced by unexpected unemployment data and shifts in Federal Reserve interest rate policies. Despite these broader market challenges, small-cap stocks often present unique opportunities for investors seeking growth potential in under-the-radar companies. Identifying promising stocks requires an understanding of how these smaller companies can navigate economic fluctuations while...

Kyverna Therapeutics (KYTX) just delivered positive topline data from its registrational KYSA-8 trial in stiff person syndrome and paired that milestone with a planned $100 million follow on equity raise, a combination the market is watching closely. See our latest analysis for Kyverna Therapeutics. The news has turbocharged sentiment, with Kyverna’s latest share price at $10.82 after a 1 day share price return of 23.23 percent and a year to date share price return of 176.02 percent. This...